# Perspectum

> Perspectum is an Oxford-based medical technology company selling cloud-delivered imaging analysis and clinical-trial services. Its software extracts quantitative biomarkers from MRI data to support the assessment and monitoring of liver, biliary and multi-organ disease, and to help pharmaceutical researchers measure treatment response.

- **Founded:** 2012
- **Headquarters:** Oxford, United Kingdom
- **Founders:** Rajarshi Banerjee (Co-founder and former CEO; departure announced January 2026), Michael Brady (Co-founder; image analysis scientist), Matthew Robson (Co-founder; historically CTO), Stefan Neubauer (Co-founder; academic clinician and MRI researcher)
- **Products:** LiverMultiScan, CoverScan, MRCP+, Hepatica, Pharma Solutions
- **Notable:** LiverMultiScan has FDA clearance and CE marking., CoverScan received FDA 510(k) clearance in May 2022., A US$55 million Series C brought cumulative funding to approximately US$140 million by March 2023, according to the company.

## Products & services

- **LiverMultiScan** — Non-contrast MRI analysis reporting liver disease activity, fat and iron; supports clinical assessment and monitoring.
- **CoverScan** — Cloud-based multiparametric MRI software for quantitative multi-organ assessment; US FDA clearance dates to 2022, with scanner-specific indications.
- **MRCP+** — Quantitative analysis and enhanced 3D visualization of bile ducts and the pancreatic duct from non-contrast MRCP images.
- **Hepatica** — Liver segment volume and tissue-characterization analysis to support pre-operative assessment and surgical planning.
- **Pharma Solutions** — Imaging biomarkers and clinical-trial services, including body composition, cardiometabolic, autoimmune, gastrointestinal and oncology applications.
- **VitruvianScan** — Body-composition characterization software listed in current product interpretation guides.

## Achievements

- LiverMultiScan has FDA clearance and CE marking.
- CoverScan received FDA 510(k) clearance in May 2022.
- A US$55 million Series C brought cumulative funding to approximately US$140 million by March 2023, according to the company.
- A 2025 peer-reviewed RADIcAL-1 publication evaluated 802 participants across four countries.
- The 2024 FDA grant supports rare-disease biomarker research; it does not establish completed biomarker qualification.

## Latest updates

- **2026-09** — Warren Cresswell appointed CEO effective 15 September.
- **2026-08** — SAM/AMI and Perspectum announced a CoverScan program in Singapore on 6 August; website listing published 18 August.
- **2026-01** — Rajarshi Banerjee’s departure announced; Rexford Newbould appointed interim CEO.
- **2025-12** — Avant Santé partnership announced on 17 December, then listed on Perspectum’s site in January 2026.
- **2025-06** — King’s College London announced LIHE partnership.
- **2025-03** — RADIcAL-1 results published in Communications Medicine.

## Links

- Website: https://perspectum.com/
- LinkedIn: https://www.linkedin.com/company/perspectum-ltd
- Twitter/X: https://twitter.com/PerspectumGroup
- YouTube: https://www.youtube.com/channel/UCCkF79McsvPEGmmED9jFLrA
- Instagram: https://www.instagram.com/perspectum.ltd/
- Facebook: https://www.facebook.com/perspectum/

---

Profile page: https://yespress.io/perspectum
Published by YesPress — https://yespress.io
Last updated: 2026-10-01